Why Single Cell for Oncology?
The heterogeneity and dynamism of cancer present formidable challenges to treating the disease. Through an iterative process of mutation and cell expansion, tumors generate genetic and phenotypic heterogeneity, contributing to the complexity of the disease.
Advances in single-cell technology are enabling researchers to precisely reconstruct tumor phylogenies and reveal the clonal architecture of tumors, with profound implications for diagnosis, prognosis, and treatment of cancer.
Mission Bio’s Tapestri Platform enables highly sensitive targeted DNA sequencing at the single-cell level, measuring SNVs, indels, chromosomal rearrangements and CNVs, as well as structural characteristics like zygosity, mutational co-occurrence, and the presence of rare cell populations. Moreover, Tapestri enables simultaneous measurement of genotype and immunophenotype across thousands of cells in a single assay to allow a thorough depiction of the tumor’s clonal diversity.
Single-cell applications in oncology
Clonal evolution
Track clonal evolution and reconstruct phylogenetic trees
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
VIEW PAPER
Tumor Profiling
Unravel tumor heterogeneity and discern early driver gene alterations
Single-cell DNA analysis with nuclei isolated from solid tumor tissue
VIEW APP NOTE
Disease Modeling
Assess genome editing for use in pre-clinical disease modeling
Single-cell DNA analysis of a novel acute erythroid leukemia (AEL) CRISPR induced mouse model
DOWNLOAD APP NOTE
Therapeutic Resistance
Reveal therapy resistance mechanisms through course of treatment
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
VIEW PAPER
Minimal Residual Disease (MRD)
Monitor disease during remission
to track MRD
Single-cell mutational profiling enhances the clinical evaluation of AML MRD
VIEW PAPER
Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Distinguish leukemic clones from age-related clonal hematopoiesis
Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis
VIEW PAPER
